FDA Urged to Explain ANDA Deficiencies to Avoid RTR Errors
This article was originally published in The Gold Sheet
Executive Summary
If FDA were more communicative about potential ANDA deficiencies, the agency could avoid refuse-to-receive missteps, generics firms say. Then industry wouldn’t have to challenge the many RTR decisions that are turning out to be flawed.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.